Gimv

Gimv strengthens its position in life sciences venture capital with the creation of a new dedicated platform

Retrieved on: 
Wednesday, June 15, 2022
Ablynx, Solution, List of life sciences, City, Drug development, Health care, VC, Pittsburgh Life Sciences Greenhouse, Euronext, Partner, Ecosystem, Consumer-driven healthcare, Investment, Immuno AG, Consumer, Patient, Johnson & Johnson, Fine chemical, Pharmaceutical industry, Video game, Gimv, Ambition

After solid growth within Gimvs existing Healthcare platform, a dedicated Life Sciences platform will strengthen the role of Gimv in the international life science VC ecosystem.

Key Points: 
  • After solid growth within Gimvs existing Healthcare platform, a dedicated Life Sciences platform will strengthen the role of Gimv in the international life science VC ecosystem.
  • The Life Sciences platform builds on the success and excellent returns generated by portfolio companies over four decades, including companies like Ablynx, where Gimv was a founding investor and Covagen, which was acquired by Johnson & Johnson.
  • Bram Vanparys*, Managing Partner and Head of Life Sciences at Gimv, said: The launch of the new Life Sciences platform represents an exciting next step for Gimv in the sector.
  • Having a VC centered Life Sciences platform separate from a PE centered Healthcare platform allows more focus for both teams while preserving potential synergies.

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

Retrieved on: 
Tuesday, June 7, 2022
Degenerative disease, Saṃsāra, Iron Stone Strategic Capital Partners, Company, Series, LILRB1, ILT2, Doctor of Philosophy, Chairperson, Lightspeed Venture Partners, HLA, CEO, KIR, ILT4, Therapy, Patient, KIR3DL1, LILRB2, Immuno-psychiatry, Novartis, Immune system, Gimv, Antibody, Autoimmune disease, General partnership, Cancer, Vaccine, Pharmaceutical industry, MD, Speed of light

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.
  • "We are delighted to close this significant financing round led by a group of top-tier U.S. and European investors," said Sean R. Smith, CEO of ImmunOs Therapeutics.
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.
  • ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.

Fredrick Goodwill Partners With Give Back Box and Fashion Influencer To Promote Sustainable Secondhand Shopping

Retrieved on: 
Wednesday, July 1, 2020
Articles, Culture, Lifestyles, Water conservation, Environmentalism, Fashion, Sustainable living, Gimv, Recycling

The Future of Fashion section highlights key solutions contributing to the creation of a conscientious future of fashion.

Key Points: 
  • The Future of Fashion section highlights key solutions contributing to the creation of a conscientious future of fashion.
  • Participants simply fill any box with donations and ship them using a prepaid label from givebackbox.com.
  • GIMV collaborated with fashion influencer, Priscilla Andalia of the Best Trends for Life blog, to spread awareness of the ways in which secondhand shopping supports a sustainable lifestyle.
  • The partnership promotes recycling, repurposing, and giving a second life to items that may otherwise end up in landfills.

JenaValve Technology Closes $50 Million Financing

Retrieved on: 
Wednesday, February 5, 2020
Medical devices, Health, Surgery, Pharmaceutical, Cardiology, Biotechnology, Medicine, Medical specialties, Heart, Cardiac surgery, Aortic valve, Percutaneous aortic valve replacement, Valve replacement, Bain Capital, Heart valve, Gimv, HDE, Aorta, the JenaValve Transfemoral TAVR System, Bain Capital Life Sciences, JenaValve

JenaValve Technology, Inc. , developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital Life Sciences .

Key Points: 
  • JenaValve Technology, Inc. , developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital Life Sciences .
  • Additional participants in the financing included existing investors Andera Partners, Gimv, Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners.
  • The Company also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the JenaValve Board of Directors.
  • This financing supports our ongoing clinical program and plans to file for U.S. Humanitarian Device Exemption (HDE) approval in the second half of 2020.

ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

Retrieved on: 
Wednesday, December 4, 2019
Immunology, Medicine, Health, Branches of biology, Boehringer Ingelheim, Idinvest Partners, Gimv, Autoimmune disease, Autoimmunity, Antibody

Life Sciences Partners (LSP), Gimv, Idinvest Partners, Kurma Partners and Boehringer Ingelheim Venture Fund that contributed to the 2017 20 Million Series A round also participated for a significant portion of this raise.

Key Points: 
  • Life Sciences Partners (LSP), Gimv, Idinvest Partners, Kurma Partners and Boehringer Ingelheim Venture Fund that contributed to the 2017 20 Million Series A round also participated for a significant portion of this raise.
  • "We believe this investment represents a strong validation of our pipeline and its potential both in cancer and autoimmune diseases.
  • In addition, preclinical experiments with ImChecks antagonist antibodies have demonstrated potential as treatments for a wide range of autoimmune diseases.
  • For further information on ImCheck: http://www.imchecktherapeutics.com and @ImCheckThx
    For further information on the participating funds:

Mérieux Equity Partners Announced That Benoit Chastaing Has Joined the Firm as Senior Partner

Retrieved on: 
Thursday, January 17, 2019
Private equity, Finance, Investment, Gimv, Leveraged buyout

Mrieux Equity Partners announced today that Benoit Chastaing has joined the firm as Senior Partner, to foster the firm's growth capital, MBO/LBO and majority investment activities relating to small and mi-cap companies within the healthcare and nutrition sectors.

Key Points: 
  • Mrieux Equity Partners announced today that Benoit Chastaing has joined the firm as Senior Partner, to foster the firm's growth capital, MBO/LBO and majority investment activities relating to small and mi-cap companies within the healthcare and nutrition sectors.
  • Benoit Chastaing brings to Mrieux Equity Partners a solid track-record in managing and financing fast growing companies within the sectors of interest of Mrieux Participations 3, the third generation vehicle recently launched with the support of several large family holdings and institutional investors.
  • Benoit was until recently an active member of the investment firm Gimv, as Partner in charge of growth capital investment in France from 2016 to 2018.
  • In this role, he led multiple majority deals such as Stiplastics Group and France Thermes and actively supported Almaviva, until its acquisition by Antin Investment Partners.